Pharmacokinetics of cyclosporine A after massive hepatectomy: A hint for small-for-size graft in living donor liver transplantation

Digestive Diseases and Sciences

Volumn 52, Issue 10, 2007, Pages 2490-2496

  Shinohara, Hisamitsu ^a   Shimada, Mitsuo ^a   Ogasawara, Takashi ^a   Morine, Yuji ^a   Ikemoto, Tetsuya ^a   Imura, Satoru ^a   Fujii, Masahiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cyclosporine; Immunosuppressants; Living donor liver transplantation; Pharmacokinetics; Small for size graft

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG METABOLISM; ENZYME BLOOD LEVEL; ENZYME METABOLISM; LIVER GRAFT; LIVER REGENERATION; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER WEIGHT; LIVING DONOR; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HEPATECTOMY; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER DISEASES; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MEMBRANE PROTEINS; ORGAN SIZE; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 34548494819     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9744-1     Document Type: Article

References (17)

1. Kiuch T, Kawasaki M, Uryuhara K, Inoue Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K (1999) Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 67:321-327
2. Sugawara Y, Makuuchi M, Takayama T, Imamura H, Dowaki S, Mizuta K, Kawarasaki H, Hashizume K (2001) Small-for-size grafts in living related liver transplantation. J Am Coll Surg 192(4):510-513
3. Shimada M, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, Yoshizumi T, Soejima Y, Suehiro T, Maehara Y (2004) Is graft size a major risk factor in living-donor adult liver transplantation? Transpl Int 17(6):310-316
4. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G (1999) Peak cyclospoline levels (Cmax) correlate with freedom from liver graft rejection: result of a prospective, randomized comparison of neural and sandimmune for liver transplantation (NOF-8). Transplantation 67(8):1133-1137
5. Fukudo M, Yano I, Masuda S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2006) Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplantation patient: twice daily vs. once daily dosing. Liver Transpl 12(2):292-300
6. Fukudo M, Yano I, Masuda S, Fukatsu S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2005) Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplantation patient. Clin Pharmacol Ther 78(2):168-181
7. Molpeceres J, Chacon M, Guzman M, Aberturas MR, Berges L (2000) Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rat after a single intravenous dose. Int J Pharm 197(1-2):129-141
8. Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K (2002) Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporine A disposition kinetics by dexamethasone. Biochem Pharmacol 63(4):777-783
9. Uwe C, Karl-Friendrich S (1995) Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 28:547-559
10. Tomlinson ES, JMaggs JL, Park BK, Back DJ (1997) Dexamethasone metabolism in vitro: species difference. J Steroid Biochem Mol Biol 62:345-352
11. Dahmen U, Gu YL, Shen K, Dirsch O, Li J, Fan LM, Broelsch CE (2002) Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. Transplant Proc 34(6):2312-2313
12. 1. Eur Surg Res 31(5):399-405
13. Higgins GM, Anderson RM (1931) Experimental pathology of the liver. Arch Pathol 12:186-202
14. Carson E, Rioux N, Nicolas O, Lebel-Talbot H, Bettina A (2005) Hamelin: quantification of expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-RCR. J Biochem Mol Toxicol 19(6):368-378
15. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-653
16. Ptachcinski RJ, Venkataramanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 11:107-132
17. Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K (2005) Long-term levotyroxine treatment decreases the oral bioavailability of cyclosporine A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet 20(5):324-330